JP Morgan Chase’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $27.4M | Buy |
57,000
+46,500
| +443% | +$25.2M | ﹤0.01% | 1819 |
|
|
2025
Q4 | $6.08M | Sell |
10,500
-15,000
| -59% | -$8.48M | ﹤0.01% | 3131 |
|
|
2025
Q3 | $12.4M | Buy |
25,500
+10,500
| +70% | +$4.89M | ﹤0.01% | 2532 |
|
|
2025
Q2 | $6.08M | Buy |
15,000
+10,000
| +200% | +$4.18M | ﹤0.01% | 2978 |
|
|
2025
Q1 | $2.49M | Buy |
+5,000
| New | +$2.71M | ﹤0.01% | 3710 |
|
|
2024
Q4 | – | Sell |
-4,000
| Closed | -$2.47M | – | 7731 |
|
|
2024
Q3 | $2.47M | Buy |
4,000
+1,600
| +67% | +$947K | ﹤0.01% | 3831 |
|
|
2024
Q2 | $1.33M | Sell |
2,400
-20,500
| -90% | -$11.7M | ﹤0.01% | 4078 |
|
|
2024
Q1 | $13.3M | Sell |
22,900
-40,700
| -64% | -$22.8M | ﹤0.01% | 2229 |
|
|
2023
Q4 | $33.8M | Buy |
63,600
+48,200
| +313% | +$23.3M | ﹤0.01% | 1460 |
|
|
2023
Q3 | $7.8M | Buy |
15,400
+10,500
| +214% | +$5.6M | ﹤0.01% | 2482 |
|
|
2023
Q2 | $2.56M | Buy |
4,900
+900
| +23% | +$486K | ﹤0.01% | 3352 |
|
|
2023
Q1 | $2.31M | Sell |
4,000
-62,100
| -94% | -$35M | ﹤0.01% | 3444 |
|
|
2022
Q4 | $36.4M | Buy |
66,100
+46,200
| +232% | +$24.5M | ﹤0.01% | 1272 |
|
|
2022
Q3 | $10.1M | Hold |
19,900
| – | – | ﹤0.01% | 2142 |
|
|
2022
Q2 | $10.8M | Sell |
19,900
-59,300
| -75% | -$32.6M | ﹤0.01% | 2094 |
|
|
2022
Q1 | $46.8M | Buy |
79,200
+50,000
| +171% | +$28.7M | 0.01% | 1200 |
|
|
2021
Q4 | $19.5M | Sell |
29,200
-8,300
| -22% | -$5.18M | ﹤0.01% | 1844 |
|
|
2021
Q3 | $21.4M | Buy |
37,500
+35,300
| +1,605% | +$19.4M | ﹤0.01% | 1707 |
|
|
2021
Q2 | $1.11M | Buy |
+2,200
| New | +$1.04M | ﹤0.01% | 4218 |
|
|
2020
Q3 | – | Sell |
-47,100
| Closed | -$17.1M | – | 5779 |
|
|
2020
Q2 | $17.1M | Buy |
+47,100
| New | +$15.8M | ﹤0.01% | 1481 |
|
|
2020
Q1 | – | Sell |
-21,700
| Closed | -$7.05M | – | 5727 |
|
|
2019
Q4 | $7.05M | Sell |
21,700
-15,000
| -41% | -$4.55M | ﹤0.01% | 2408 |
|
|
2019
Q3 | $10.7M | Hold |
36,700
| – | – | ﹤0.01% | 2092 |
|
|
2019
Q2 | $10.8M | Sell |
36,700
-600
| -2% | -$165K | ﹤0.01% | 2055 |
|
|
2019
Q1 | $10.2M | Sell |
37,300
-10,100
| -21% | -$2.51M | ﹤0.01% | 2027 |
|
|
2018
Q4 | $10.6M | Buy |
47,400
+18,000
| +61% | +$4.22M | ﹤0.01% | 1963 |
|
|
2018
Q3 | $7.18M | Sell |
29,400
-8,000
| -21% | -$1.84M | ﹤0.01% | 2466 |
|
|
2018
Q2 | $7.75M | Buy |
+37,400
| New | +$7.94M | ﹤0.01% | 2343 |
|
|
2017
Q4 | – | Sell |
-50,000
| Closed | -$9.32M | – | 5576 |
|
|
2017
Q3 | $9.32M | Buy |
50,000
+9,500
| +23% | +$1.72M | ﹤0.01% | 2044 |
|
|
2017
Q2 | $7.07M | Buy |
40,500
+2,400
| +6% | +$403K | ﹤0.01% | 2233 |
|
|
2017
Q1 | $5.85M | Buy |
+38,100
| New | +$5.82M | ﹤0.01% | 2330 |
|
|
2015
Q1 | – | Sell |
-100,000
| Closed | -$12.5M | – | 4266 |
|
|
2014
Q4 | $12.5M | Hold |
100,000
| – | – | ﹤0.01% | 1787 |
|
|
2014
Q3 | $12.2M | Buy |
+100,000
| New | +$12.2M | ﹤0.01% | 1790 |
|
Other funds holding TMO
VCM
VPM
JP Morgan Chase's TMO Position: Q1 2026 in Review
JP Morgan Chase increased its Thermo Fisher Scientific (TMO) stake by 2.8% in Q1 2026, buying an estimated $99.6M and bringing the position to 6,795,482 shares worth $3.26B. The position accounts for 0.21% of the portfolio, ranked #103.
JP Morgan Chase first reported a position in TMO in Q2 2013 and has held it in 52 quarters since. The position peaked at $5.04B in Q1 2025. 2,588 funds tracked by Wall St. Rank hold TMO as of Q1 2026.
- JP Morgan Chase held 6,795,482 shares of Thermo Fisher Scientific worth $3.26B as of Q1 2026.
- JP Morgan Chase bought 183,604 Thermo Fisher Scientific shares in Q1 2026, an estimated $99.6M.
- Thermo Fisher Scientific made up 0.21% of JP Morgan Chase's portfolio in Q1 2026, its #103 holding.
- JP Morgan Chase first reported a position in Thermo Fisher Scientific in Q2 2013 and has held it in 52 quarters since.
- JP Morgan Chase's Thermo Fisher Scientific position peaked at $5.04B in Q1 2025.
- 2,588 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q1 2026.
Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.